Ernexa Therapeutics (ERNA) shares were down 9% in premarket activity on Friday, a day after the company effected a reverse 1-for-15 stock split.
The biotech company's shares began trading on a split-adjusted basis on Thursday.
The company stated that it implemented the split to regain compliance with the $1.00 minimum bid price required for continued listing on Nasdaq.